Literature DB >> 34160250

SARS-CoV-2 spike protein induces paracrine senescence and leukocyte adhesionin endothelial cells.

Keith Meyer1, Tapas Patra1, Ranjit Ray1,2.   

Abstract

Increased mortality in COVID-19 often associates with microvascular complications. We have recently shown that SARS-CoV-2 spike protein promotes an inflammatory cytokine IL-6/IL-6R induced trans-signaling response and alarmin secretion. Virus infected or spike transfected human epithelial cells exhibited an increase in senescence state with the release of senescence associated secretory proteins (SASP) related inflammatory molecules. Introduction of BRD4 inhibitor AZD5153 to senescent epithelial cells reversed this effect and reduced SASP related inflammatory molecule release in TMNK-1 or EAhy926 as representative human endothelial cell line, when exposed to cell culture medium (CM) derived from A549 cells expressing SARS-CoV-2 spike protein, also exhibited a senescence phenotype with enhanced p16, p21, SA-β-galactosidase expression, and triggered SASP pathways. Inhibition of IL-6 trans-signaling by Tocilizumab and inhibition of inflammatory receptor signaling by the BTK inhibitor Zanubrutinib, prior to exposure of CM to endothelial cells, inhibited p21 and p16 induction. We also observed an increase in reactive oxygen species (ROS) in A549 spike transfected and endothelial cells exposed to spike transfected CM. ROS generation in endothelial cell lines was reduced after treatment with Tocilizumab and Zanubrutinib. Cellular senescence was associated with an increased level of the endothelial adhesion molecules, VCAM-1 and ICAM-1 with in vitro leukocyte attachment potential. Inhibition of senescence or SASP function prevented VCAM-1/ICAM-1 expression and leukocyte attachment. Taken together, we identified that the exposure of human endothelial cells to cell culture supernatant derived from SARS-CoV-2 spike protein expression displayed cellular senescence markers, leading to enhanced leukocyte adhesion. Importance: The present study was aimed at examining the underlying mechanism of extrapulmonary manifestations of SARS-CoV-2 spike protein associated pathogenesis, with the notion that infection of the pulmonary epithelium can lead to mediators that drive endothelial dysfunction. We utilized SARS-CoV-2 spike protein expression in cultured cells of human hepatocytes (Huh7.5) and pneumocytes (A549) to generate conditioned culture media (CM). Endothelial cell lines (TMNK-1 or EAhy926) treated with CM exhibited increase in cellular senescence markers by a paracrine mode, and lead to leukocyte adhesion. Overall, the link between these responses in endothelial cell senescence, and a potential contribution to microvascular complication in productively SARS-CoV-2 infected humans is implicated. Furthermore, the use of inhibitors (BTK, IL-6 and BRD4) showed reverse effect in the senescent cells. These results may support the selection of potential adjunct therapeutic modalities to impede SARS-CoV-2 associated pathogenesis.

Entities:  

Year:  2021        PMID: 34160250     DOI: 10.1128/JVI.00794-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Ranjit Ray; Ratna B Ray
Journal:  mBio       Date:  2022-05-19       Impact factor: 7.786

Review 2.  Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia.

Authors:  Marco Chilosi; Claudio Doglioni; Claudia Ravaglia; Guido Martignoni; Gian Luca Salvagno; Giovanni Pizzolo; Vincenzo Bronte; Venerino Poletti
Journal:  Biomedicines       Date:  2022-06-06

Review 3.  Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?

Authors:  Theoharis C Theoharides
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.682

Review 4.  Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases.

Authors:  Andy Ruiz; Julio Flores-Gonzalez; Ivette Buendia-Roldan; Leslie Chavez-Galan
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

5.  Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis.

Authors:  Konstantinos Evangelou; Dimitris Veroutis; Koralia Paschalaki; Periklis G Foukas; Nefeli Lagopati; Marios Dimitriou; Angelos Papaspyropoulos; Bindu Konda; Orsalia Hazapis; Aikaterini Polyzou; Sophia Havaki; Athanassios Kotsinas; Christos Kittas; Athanasios G Tzioufas; Laurence de Leval; Demetris Vassilakos; Sotirios Tsiodras; Barry R Stripp; Argyris Papantonis; Giovanni Blandino; Ioannis Karakasiliotis; Peter J Barnes; Vassilis G Gorgoulis
Journal:  Eur Respir J       Date:  2022-08-18       Impact factor: 33.795

6.  Post-treatment with propofol inhibits inflammatory response in LPS-induced alveolar type II epithelial cells.

Authors:  Xilun Yang; Ling Ma
Journal:  Exp Ther Med       Date:  2022-01-31       Impact factor: 2.447

7.  Concerns over functional experiments, interpretation, and required controls. Reply.

Authors:  Wan-Chen Hsieh; Shih-Yu Chen
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

8.  Are There Hidden Genes in DNA/RNA Vaccines?

Authors:  Christopher A Beaudoin; Martin Bartas; Adriana Volná; Petr Pečinka; Tom L Blundell
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

9.  SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection.

Authors:  John D Imig
Journal:  Clin Sci (Lond)       Date:  2022-03-31       Impact factor: 6.124

10.  SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.

Authors:  Luca Perico; Marina Morigi; Miriam Galbusera; Anna Pezzotta; Sara Gastoldi; Barbara Imberti; Annalisa Perna; Piero Ruggenenti; Roberta Donadelli; Ariela Benigni; Giuseppe Remuzzi
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.